Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates.

[1]  Weizhong Yang,et al.  Epidemiology of human infections with avian influenza A(H7N9) virus in China. , 2014, The New England journal of medicine.

[2]  P. Wilson,et al.  Divergent H7 Immunogens Offer Protection from H7N9 Virus Challenge , 2014, Journal of Virology.

[3]  L. Zon.  Analysis of epidemioiogical characteristics on human infection with avian influenza H7N9 virus cases , 2014 .

[4]  G. Glenn,et al.  A recombinant viruslike particle influenza A (H7N9) vaccine. , 2013, The New England journal of medicine.

[5]  Z. Wei,et al.  Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. , 2013, Vaccine.

[6]  Nicholas S. Kelley,et al.  Major challenges in providing an effective and timely pandemic vaccine for influenza A(H7N9). , 2013, JAMA.

[7]  A. García-Sastre,et al.  Induction of Cross-Reactive Antibodies to Novel H7N9 Influenza Virus by Recombinant Newcastle Disease Virus Expressing a North American Lineage H7 Subtype Hemagglutinin , 2013, Journal of Virology.

[8]  Jie Dong,et al.  Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .

[9]  A. D. De Groot,et al.  Low immunogenicity predicted for emerging avian-origin H7N9 , 2013, Human vaccines & immunotherapeutics.

[10]  Robert B. Couch,et al.  A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine , 2012, PloS one.

[11]  Boping Zhou,et al.  A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses , 2012, Journal of Virology.

[12]  J. Langley,et al.  Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. , 2010, The Journal of infectious diseases.

[13]  R. Rappuoli,et al.  Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus , 2010, Science Translational Medicine.

[14]  I. Donatelli,et al.  A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. , 2009, Vaccine.

[15]  O. Engelhardt,et al.  Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). , 2008, Vaccine.

[16]  A. Osterhaus,et al.  For Personal Use. Only Reproduce with Permission from the Lancet , 2022 .

[17]  Marion Koopmans,et al.  Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. García-Sastre,et al.  Rescue of influenza A virus from recombinant DNA. , 2007, Journal of virology.

[19]  Tokiko Watanabe,et al.  Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Keiji Fukuda,et al.  Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays , 1999, Journal of Clinical Microbiology.

[21]  J. Oxford,et al.  Quantitative analysis of the protein composition of influenza A and B viruses using high resolution SDS polyacrylamide gels. , 1981, Journal of biological standardization.

[22]  G. K. Hirst.  THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION , 1942, The Journal of experimental medicine.